Fibroadenoma

Why Reassurance with routine clinical follow-up is correct

• Her exam, ultrasound (oval, circumscribed, parallel, hypoechoic) and core biopsy all agree on a simple fibroadenoma. It is benign, does not raise her breast cancer risk, and often stays stable or shrinks over time.
• The ASBrS/SBI 2025 guideline (Rosenberger et al., JAMA Surg 2025) says fibroadenomas proven by a concordant core biopsy do not need imaging follow-up. She can return to age-appropriate screening and needs new imaging only if the mass grows, becomes symptomatic or changes on exam.
• She has none of the guideline's reasons for removal (symptoms, patient preference, large size or substantive growth), so reassurance with routine clinical follow-up is the right first step.

Why the others are wrong

• Surgical excision of the breast lesion — Under ASBrS/SBI 2025, a concordant fibroadenoma without atypia is removed only if it causes symptoms, is large, is clearly growing, or the patient wants it out. Atypia on biopsy or a suspected phyllodes tumor also calls for excision. This stable 1.5-cm mass has none of these.
• Ultrasound-guided percutaneous cryoablation — This FDA-cleared minimally invasive treatment is an alternative to surgery for selected small fibroadenomas when the patient wants the lesion removed. A stable, asymptomatic, biopsy-proven fibroadenoma needs no treatment.
• Vacuum-assisted repeat core needle biopsy — Repeat sampling is for a nondiagnostic specimen or a mismatch between imaging and pathology (excision is the other option there). Features of phyllodes tumor, such as rapid growth or cellular stroma, call for excisional biopsy rather than another core. Her benign result fits the classic ultrasound appearance, so another biopsy adds nothing.
• Diagnostic mammography of both breasts — tempting because mammography is the imaging test most linked with breast masses, but under age 30 dense glandular tissue limits its yield and ultrasound is the first imaging test; her mass is already characterized on ultrasound and proven benign by a concordant core biopsy, so mammography adds nothing and she can return to age-appropriate screening.

Additional high-yield points

• Know the two follow-up paths. A probably benign (BI-RADS 3) mass that is not biopsied gets short-interval ultrasound, first at about 6 months. A concordant benign core biopsy ends the need for imaging surveillance.
• Ultrasound is the first imaging test for a palpable breast mass in a woman under 30. Diagnostic mammography becomes an option from age 30 and is standard from 40.
• Complex fibroadenomas (cysts >3 mm, sclerosing adenosis, epithelial calcifications, papillary apocrine change) carry a modestly higher breast cancer risk. A fibroepithelial mass that grows quickly should be excised to rule out phyllodes tumor.

Why A rubbery mobile mass with well-defined borders is correct

• Fibroadenoma is the most common discrete breast mass in women under 30 and represents a benign proliferation of stroma and epithelium.
• On palpation it is solitary, painless, firm but rubbery, and so mobile that it slides away from the examining finger, which is why it is often called a breast mouse.
• Sharply defined borders and free mobility within the breast are the bedside features that separate it from carcinoma, which is hard, irregular, and poorly mobile.
• In a 19-year-old with a painless discrete lump and no risk factors, a rubbery mobile mass with well-defined borders is the expected finding.

Why the others are wrong

• A firm mass fixed to the underlying chest wall — fixation suggests local invasion and would be extraordinary at this age. Note that pectoralis muscle involvement alone does not make a tumor T4: T4a requires extension to the chest wall proper, meaning rib, intercostal muscle or serratus anterior.
• A soft mass that changes in size with the cycle — hormonally responsive size change describes a simple cyst or fibrocystic change, whereas a fibroadenoma is typically stable across the menstrual cycle.
• An irregular mass with overlying skin dimpling — irregular margins plus skin tethering from shortened Cooper ligaments are hallmarks of invasive carcinoma and are not features of a fibroadenoma.
• A large bulky mass with stretched shiny overlying skin — this is the picture of a large, rapidly growing fibroepithelial lesion such as a phyllodes tumor, which peaks in the 40s, or, in adolescents, a giant juvenile fibroadenoma; nothing in this history suggests a large or fast-growing mass, so a painless lump noticed 2 months ago in a 19-year-old is far more likely an ordinary small fibroadenoma that feels rubbery and mobile.

Every dominant breast mass still deserves triple assessment; in women under 30 the first imaging study is ultrasound rather than mammography because of dense fibroglandular tissue.